RO103684B1 - Production method of immuno-globulin a1(iga1) - Google Patents
Production method of immuno-globulin a1(iga1)Info
- Publication number
- RO103684B1 RO103684B1 RO138173A RO13817389A RO103684B1 RO 103684 B1 RO103684 B1 RO 103684B1 RO 138173 A RO138173 A RO 138173A RO 13817389 A RO13817389 A RO 13817389A RO 103684 B1 RO103684 B1 RO 103684B1
- Authority
- RO
- Romania
- Prior art keywords
- iga1
- nan3
- buffer
- k2hpo4
- nacl
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Procedeul conform inventiei consta în aceea ca plasma de mielom IgA1, selectionata a fi cât mai bogata în IgA1 si cât mai saraca în IgG, este defibrinata cu CaCl2 si apoi tratata cu 25 g (NH4)2SO4 la 100 ml la 4 degree C, dupa centrifugare precipitatul se spala de doua ori cu solutie (NH4)2SO4, 25 g 100 ml apa si reluat în tampon Na3PO4/H3PO4 0,03 M pH'5, ce contine 0,3 M NaCl si o,o2% NaN3, apoi cromatografiat pe DEAE Affi Gel-Blue, eluaeea se face cu acelasi tampon si primul peak se concentreaza si se echilibreaza cu tampon K2HPO4 0,02 M pH'8, ce contine 0,02% NaN3 si se trece pe aceeasi coloana cromatografica regenerata si echilibrata cu acest tampon, în final IgA1 este eluata cu 0,1 M NaCl în tampon K2HPO4 0,02 M pH'8, ce contine 0,02 NaN3.The process according to the invention consists in that IgA1 myeloma plasma selected as being as rich in IgA1 and as poor as IgG is defibrinated with CaCl2 and then treated with 25 g (NH4) 2 SO4 per 100 ml at 4 ° C after centrifugation, the precipitate was washed twice with (NH4) 2 SO4 solution, 25 g of 100 mL of water, and resuspended in 0.03 M NaHPO4 / H3PO4 pH5 containing 0.3M NaCl and 0.2% NaN3, then chromatographed on DEAE Affi Gel-Blue, the eluate is made with the same buffer and the first peak is concentrated and equilibrated with K2HPO4 0.02 M pH8 buffer containing 0.02% NaN3 and passed to the same regenerated and balanced chromatographic column this buffer, finally IgA1 is eluted with 0.1 M NaCl in K2HPO4 0.02 M pH8, containing 0.02 NaN3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO138173A RO103684B1 (en) | 1989-02-10 | 1989-02-10 | Production method of immuno-globulin a1(iga1) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO138173A RO103684B1 (en) | 1989-02-10 | 1989-02-10 | Production method of immuno-globulin a1(iga1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RO103684A2 RO103684A2 (en) | 1991-12-09 |
| RO103684B1 true RO103684B1 (en) | 1992-03-25 |
Family
ID=20123980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO138173A RO103684B1 (en) | 1989-02-10 | 1989-02-10 | Production method of immuno-globulin a1(iga1) |
Country Status (1)
| Country | Link |
|---|---|
| RO (1) | RO103684B1 (en) |
-
1989
- 1989-02-10 RO RO138173A patent/RO103684B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RO103684A2 (en) | 1991-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1577795A (en) | Endotoxin reduction or removal process | |
| CA1208130A (en) | Ultrapurification of factor viii | |
| ZA961679B (en) | Process for producing a protein | |
| Berglund et al. | Synthesis of ATP‐and dATP‐Substituted Sepharoses and Their Application in the Purification of Phage‐T4–Induced Ribonucleotide Reductase | |
| PL310435A1 (en) | Method of obtaining anti-d immunoglobulin g concentrate and pharmaceutical agent containing same | |
| TW281705B (en) | ||
| ES8100763A1 (en) | Prothrombin complex concentrates,preparation and application thereof | |
| GB9009106D0 (en) | Processes and intermediates for synthetic antibody derivatives | |
| Sakai et al. | Stimulation of cyclic nucleotide phosphodiesterases from rat brain by activator protein, proteolytic enzymes and a vitamin E derivative | |
| FR2632524B1 (en) | PROCESS FOR THE PREPARATION OF A CONCENTRATED FRACTION IN FACTOR VIIA AND ITS APPLICATION AS A MEDICAMENT | |
| RO103684B1 (en) | Production method of immuno-globulin a1(iga1) | |
| DE3479503D1 (en) | Process for the preparation of an antithrombin iii-heparin, e.g. an antithrombin iii-heparinoid concentrate | |
| SE8401664D0 (en) | PROCEDURE FOR PURIFYING TYLOSIN | |
| NO174415C (en) | Clamp body, as well as process for its manufacture | |
| DE69637464D1 (en) | THERAPEUTIC FRAGMENTS OF THE "VON WILLEBRAND" FACTOR | |
| Moss et al. | Effects of chymotrypsin and a calcium-dependent protein activator on guanosine 3′, 5′-monophosphate phosphodiesterase from rat liver | |
| AU1593583A (en) | Improvements in or relating to the production of antiviral agents | |
| Sawai et al. | Synthesis of oligoinosinates with 2'-5'internucleotide linkage in aqueous solution using Pb2+ ion. | |
| EP0229026A3 (en) | Therapeutic blood product, means and methods of preparing same | |
| ES8503954A1 (en) | Products for use in treating cancer. | |
| Valentini et al. | Structural and functional heterogeneity of single-stranded DNA-binding proteins from calf thymus | |
| EP0207043A3 (en) | Process for treating glass to prevent its efflorescence, and glass treated according to this process | |
| Wallin et al. | Purification from bovine blood of the warfarin-induced precursor of prothrombin | |
| HU900525D0 (en) | Process for the production of medical preparations for treating endotoxinemy | |
| GB1197415A (en) | Process for the Purification of Reduced Pyridine Coenzymes |